8-K - Decoy Therapeutics Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Decoy Therapeutics Inc. regained compliance with Nasdaq's Minimum Bid Price Requirement following a reverse stock split, with confirmation on March 31, 2026, and will be subject to a Mandatory Panel Monitor until March 31, 2027.

Key Takeaways

1Company received Nasdaq non-compliance notice on December 31, 2025, for bid price below $1.00 for 30 consecutive business days.

2Implemented reverse stock split effective March 6, 2026, trading on split-adjusted basis from March 9, 2026.

3Hearings Panel granted exception period until March 20, 2026, to achieve $1.00 bid price for 10 consecutive business days.

4Common stock closed at $7.47 on March 20, 2026, meeting compliance requirement.

5Nasdaq confirmed full compliance with all listing requirements on March 31, 2026.

6Subject to Mandatory Panel Monitor until March 31, 2027, with potential delisting hearing if non-compliant.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. Other Events As previously reported, on December 31, 2025, Decoy Therapeutics Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“

Other Event

$1.00$1.00$7.47$1.00

9.01

Financial Statements and Exhibits. (d) Exhibits | Exhibit Number | | Exhibit Description | |---|---|---| | | | | | 99.1 | | Press Release of Decoy Therapeutics

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1